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Introduction:  Leptotrichia spp. were the 
initial microbes seen by van Leeuwenhoek in 
1683. Only recently have Leptotrichia been 
recognized as pathogens. Little information is 
available in the literature. These aerotolerant, 
anaerobic, fusiform gram negative rods are 
normal flora of mouth, GI tract and vagina. 
Neutropenic patients with mucositis have 
been known to develop L. buccalis sepsis, 
but recently L. trevisanii has been shown to 
cause sepsis in this setting. Timely 
recognition allows effective treatment, but 
clinician and microbiologist suspicion is 
required due to conventional identification 
difficulties and delays with 16S rRNA 
sequencing. Currently, there are only two 
published case reports of L. trevisanii 
bacteremia. We recently identified four 
patients with Leptotrichia bacteremia over the 
past year; two of which were L. trevisanii and 
are described here. 
Discussion: Leptotrichia spp. may cause up 
to 16% of anaerobic bacteremias in patients 
with hematologic malignancies.  Leptotrichia 
spp. are generally resistant to quinolones, a 
mainstay of antibacterial prophylaxis in 
neutropenic patients. Delays in identification 
require early suspicion for initiation of 
effective therapy, especially in the febrile, 
neutropenic patient with mucositis. 
Case reports: Patient 1, a 63 year-old with IgGκ multiple myeloma, was treated with melphalan and 
autologous stem cell transplantation (SCT). On day 8 post-SCT, he developed mucositis and febrile 
neutropenia while on levofloxacin. Blood cultures were drawn and grew anaerobic GNR two days 
later. He remained intermittently febrile despite line removal and treatment with meropenem and 
vancomycin. Six days later, he was again febrile and was switched to ertapenem with resolution of 
fever. L. trevisanii was identified on day 9 by16S rRNA sequencing. Patient 2, a 56 year-old with 
myelodysplastic syndrome, had a matched sibling donor SCT. Eight months later, she developed 
acute myelogenous leukemia. After induction therapy, she developed mucositis and febrile 
neutropenia while on levofloxacin. Blood cultures grew L. trevisanii, again confirmed by 16S rRNA 
sequencing. She remained afebrile after line removal and treatment with cefepime. 
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Gram stains of Leptotrichia trevisanii from solid media (top) and positive blood culture (above) both courtesy of Marsha Wilson, MT.  
